Please select an option below to help us tailor your newsletter to best suit your content interests!
A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)
VIEW TRIAL ON CLINICALTRIALS.GOVBladder cancer, urothelial carcinoma
Stage 4
Phase 1
Open to Enrollment
Evorpacept
Fusion protein blocking CD47-SIRPalpha
Dan Vaena, MD
ALX Oncology
Urothelial carcinoma
ON TARGET: A Phase 3 multicenter, randomized, double-blind placebo-controlled trial evaluating crofelemer for the prophylaxis of diarrhea in adult patients with solid tumors
receiving targeted-cancer therapies with or without standard chemotherapy regimens
Breast, Lung, Bladder, Gastric, Esophageal, Kidney, Renal, RCC, NSCLC, Melanoma, thyroid, sarcoma, liver, HCC, GIST, PNET,
Stage 4
Phase 3
Open to Enrollment
Any
Crofelemer
Botanical oligomeric proanthocyanidin
Lee Schwartzberg, MD
Napo Pharmaceuticals
Any
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVRenal cell carcinoma, hormone receptor positive breast cancer, castration-resistant prostate cancer, urothelial cancer, colorectal cancer (HR+ BC, RCC, CRPC, Bladder, CRC)
Stage 4
Phase 1
Open to Enrollment
Generally at least 1 prior line. Some exceptions
XL092
VEGF/MET kinase inhibitor
Dan Vaena, MD
Exelixis
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVEsophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage 4
Phase 1
Open to Enrollment
>1st line
RO7502175
Anti-CCR8 antibody
Dan Vaena, MD
Genentech, Inc.
Carcinoma
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVPancreatic, Esophageal, Gastric, Colorectal, Breast, Lung, Prostate, Melanoma, Head and Neck, Sarcoma, Bladder, Renal Cell, Ovarian, Endometrial, Cervical
Stage 4
Phase 1
Open to Enrollment
Late line
OBI-999
Globo H targeting agent
Dan Vaena, MD
OBI Pharma
Any solid tumor
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVUrothelial Neoplasm, Bladder Cancer, Renal Cell Carcinoma, Head and Neck, Lung Cancer, NSCLC, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Melanoma
Stage 4
Phase 1
Open to Enrollment
1st or later
DSP-7888
peptide vaccine stimulating cytotoxic T-cells expressing WT1
Dan Vaena, MD
Sumitomo Dainippon Pharma Oncology Inc.
Carcinoma
A Phase 1a/1b study of COM701 as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.
VIEW TRIAL ON CLINICALTRIALS.GOVOvarian, uterine, endometrial, breast, TNBC, lung, colon, CRC, NSCLC, head and neck, SCCHN, gastric, stomach, kidney, renal, RCC, bladder, transitional cell,
Stage 4
Phase 1
Open to Enrollment
Late line
COM-701, PD(L)-1 antibody
PVRIG monoclonal antibody, PD(L)-1 antibody
Dan Vaena, MD
Compugen